accountMerck CEO Kenneth Frazier Even as failures in the field pile up, Merck ($MRK) CEO Kenneth Frazier is pushing ahead with a massive development program for a drug to boost HDL or "good" cholesterol. And despite growing doubts about the prospects for such treatments, he appears to see the risky bet worth the potential payoff if the company's experimental therapy, anacetrapib, succeeds in...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Merck CEO pledges to persist with 'good' cholesterol drug program
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account